Personalized CtDNA Analysis Detects Minimal Residual Disease
By LabMedica International staff writers Posted on 08 Jun 2021 |
Image: Bone marrow aspirate showing mature plasma cells with eccentric nuclei and abundant basophilic cytoplasm indicative of multiple myeloma (Photo courtesy of Dr. David Israel Garrido, MD et.al.)
Multiple myeloma (MM), is a type of bone marrow cancer. It is called multiple myeloma as the cancer often affects several areas of the body, such as the spine, skull, pelvis and ribs. Minimal residual disease (MRD) is the name given to small numbers of leukemic cells that remain in the person during treatment, or after treatment when the patient is in remission.
Despite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), MM patients invariably relapse. MRD-negativity post-AHCT has emerged as the most important prognostic marker. Currently, MRD in MM is monitored via bone marrow aspirate sampling. Marrow MRD assays are limited by the spatial heterogeneity of marrow MM localization; extramedullary disease and sampling variability of marrow aspiration.
Hematologists at the Medical College of Wisconsin (Milwaukee, WI, USA) and their colleagues, analyzed in a retrospective, single-center study, circulating tumor DNA (ctDNA) MRD in blood samples collected from 28 patients with MM after upfront AHCT. A total of 80 plasma time points were available pre and post AHCT with a median follow-up of 92.4 months. Multiparameter flow cytometry (MFC) at 10-4 level was used to assess the MRD from the BM biopsy.
Individual bone marrow aspirates or Formalin-fixed, Paraffin-embedded (FFPE) slides from the time of MM diagnosis and matched normal blood were whole-exome sequenced, and somatic mutations were identified. MRD assessment at three months post-AHCT was performed by ctDNA analysis using a personalized, tumor-informed Signatera bespoke mPCR NGS assay (Natera Inc, San Carlos, CA, USA). The prognostic value of ctDNA was evaluated by correlating MRD status with clinical outcomes.
The scientists reported that ctDNA was detectable in 17/24 (70.8%) of pre-AHCT, 15/28 (53.6%) of ̃three months post-AHCT, and 11/28 (39.2%) of patients during the surveillance phase post-AHCT. Of the 15 ctDNA MRD positive patients, 93.3% experienced relapse on follow-up (hazard ratio: 5.64). Patients negative for ctDNA at three months post-AHCT had significantly superior progression-free survival (PFS) compared to positive (median PFS, 84 months versus 31 months) The positive predictive value (PPV) for relapse among patients positive for ctDNA at three months post-AHCT was 93.3%, and significantly higher than marrow multiparametric flow cytometry (MFC) of 68.4%.
The authors concluded that their study shows the feasibility that a tumor-informed assay on archival blood samples is predictive of relapse post-AHCT. Future prospective studies with real-time marrow next generation sequencing (NGS) and ctDNA samples are needed to define the role of ctDNA in MM and its prognostic significance. The study was presented at the virtual 2021 ASCO Annual Meeting held June 4-8, 2021.
Related Links:
Medical College of Wisconsin
Natera Inc
Despite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), MM patients invariably relapse. MRD-negativity post-AHCT has emerged as the most important prognostic marker. Currently, MRD in MM is monitored via bone marrow aspirate sampling. Marrow MRD assays are limited by the spatial heterogeneity of marrow MM localization; extramedullary disease and sampling variability of marrow aspiration.
Hematologists at the Medical College of Wisconsin (Milwaukee, WI, USA) and their colleagues, analyzed in a retrospective, single-center study, circulating tumor DNA (ctDNA) MRD in blood samples collected from 28 patients with MM after upfront AHCT. A total of 80 plasma time points were available pre and post AHCT with a median follow-up of 92.4 months. Multiparameter flow cytometry (MFC) at 10-4 level was used to assess the MRD from the BM biopsy.
Individual bone marrow aspirates or Formalin-fixed, Paraffin-embedded (FFPE) slides from the time of MM diagnosis and matched normal blood were whole-exome sequenced, and somatic mutations were identified. MRD assessment at three months post-AHCT was performed by ctDNA analysis using a personalized, tumor-informed Signatera bespoke mPCR NGS assay (Natera Inc, San Carlos, CA, USA). The prognostic value of ctDNA was evaluated by correlating MRD status with clinical outcomes.
The scientists reported that ctDNA was detectable in 17/24 (70.8%) of pre-AHCT, 15/28 (53.6%) of ̃three months post-AHCT, and 11/28 (39.2%) of patients during the surveillance phase post-AHCT. Of the 15 ctDNA MRD positive patients, 93.3% experienced relapse on follow-up (hazard ratio: 5.64). Patients negative for ctDNA at three months post-AHCT had significantly superior progression-free survival (PFS) compared to positive (median PFS, 84 months versus 31 months) The positive predictive value (PPV) for relapse among patients positive for ctDNA at three months post-AHCT was 93.3%, and significantly higher than marrow multiparametric flow cytometry (MFC) of 68.4%.
The authors concluded that their study shows the feasibility that a tumor-informed assay on archival blood samples is predictive of relapse post-AHCT. Future prospective studies with real-time marrow next generation sequencing (NGS) and ctDNA samples are needed to define the role of ctDNA in MM and its prognostic significance. The study was presented at the virtual 2021 ASCO Annual Meeting held June 4-8, 2021.
Related Links:
Medical College of Wisconsin
Natera Inc
Latest Molecular Diagnostics News
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection